NasdaqCM - Nasdaq Real Time Price USD

Outlook Therapeutics, Inc. (OTLK)

1.8500

+0.0800

+(4.52%)

At close: June 3 at 4:00:00 PM EDT

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gam

GlobeNewswire yesterday

OTLK
+4.52%
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The commo

GlobeNewswire 11 days ago

OTLK
+4.52%
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may b

GlobeNewswire 12 days ago

OTLK
+4.52%
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal yea

GlobeNewswire 19 days ago

OTLK
+4.52%
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announce

GlobeNewswire last month

OTLK
+4.52%
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigat

GlobeNewswire 3 months ago

OTLK
+4.52%
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. As part of th

GlobeNewswire 3 months ago

OTLK
+4.52%
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an op

GlobeNewswire 3 months ago

OTLK
+4.52%
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial Watch the “What This Means” segment here ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular dege

GlobeNewswire 3 months ago

OTLK
+4.52%
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role

GlobeNewswire 3 months ago

OTLK
+4.52%
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safetyONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeksCompany on track for anticipated BLA resubmission in calendar Q1 2025 ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval

GlobeNewswire 4 months ago

OTLK
+4.52%
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:00 PM ETISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Lawrence A. Kenyon, Executive Vice President, CFO and Inte

GlobeNewswire 4 months ago

OTLK
+4.52%
Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.4% and

PREMIUM
MT Newswires 4 months ago

OTLK
+4.52%
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

Outlook Therapeutics' (OTLK) shares were down more than 8% in Thursday trading after the company sai

PREMIUM
MT Newswires 4 months ago

OTLK
+4.52%
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients. ONS-5010 demonstrated non-inferiority to Novartis AG (NYSE:NVS) / Roche Holdings AG’s (OTC:RHHBY) Lucentis (ranibizumab) at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License

Benzinga 4 months ago

OTLK
+4.52%

NVS
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in gross proceeds ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an

GlobeNewswire 4 months ago

OTLK
+4.52%
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company that focuses on retinal diseases saw its stock price upped 18.24% on Friday after its financial results for fiscal years 2024 announced despite net loss. For the fiscal year 2024, Outlook Therapeutics booked net loss of $75.4 million compared to loss of $59 million in the previous year. Despite deeper loss, the loss per share reduced to $4.06 only from $4.72, as the result of reverse stock split that took place on March 2024.

GuruFocus.com 5 months ago

OTLK
+4.52%
Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics ( (OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its investors. Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for retinal diseases, particularly wet age-related macular degeneration (AMD), with its product LYTENA V A™ being the first approved ophthalmic formulation of bevacizumab in the EU and UK. The company recently announced its financial results for

TipRanks 5 months ago

OTLK
+4.52%
Outlook Therapeutics provides ONS-5010/LYTENAVA update

In May 2024, the European Commission granted Marketing Authorization for LYTENAVA for the treatment of wet AMD in the EU. Additionally, in July 2024, the UK Medicines and Healthcare products Regulatory Agency granted Marketing Authorization for LYTENAVA for the same indication in the UK. In December 2024, the National Institute for Health and Care Excellence recommended LYTENAVA as an option for the treatment of wet AMD. Plans for a potential 2025 launch in the UK and Germany are ongoing. Outloo

TipRanks 5 months ago

OTLK
+4.52%
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli

GlobeNewswire 5 months ago

OTLK
+4.52%

Performance Overview

Return	OTLK	S&P 500 (^GSPC)
YTD	-2.12%	+1.51%
1-Year	-73.57%	+13.00%
3-Year	-90.93%	+45.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sector Update: Health Care Stocks Rise Late Afternoon

Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics provides ONS-5010/LYTENAVA update

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Performance Overview